Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02847702 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Analgesic Efficacy and Safety of VM902A in Subjects With Osteoarthritis (OA) of the Knee
A Phase 2 study, sponsored by Purdue Pharma.
- Terminated
- Registry status
- Phase 2
- Development phase
- 75
- Enrollment target
NCT02847702 is a Phase 2 study that was terminated before completion, run by Purdue Pharma. The registered enrollment target is 75 participants.
The verdict
NCT02847702, a Phase 2 study, was terminated before completion, sponsored by Purdue Pharma.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 75 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the analgesic efficacy, safety, and tolerability of VM902A twice daily compared to placebo in subjects with moderate to severe chronic pain due to OA of the knee.
Interventions
- DRUG Placebo
- DRUG VM902A 200-mg Capsules
- DRUG VM902A 400-mg Capsules
- DRUG Naproxen 500-mg Capsules
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2016-08 |
| Est. Completion | 2016-11-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02847702
The ClinicalTrials.gov registry entry for NCT02847702 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Purdue Pharma, which has 54 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT02847702 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02847702 about?
NCT02847702 is a clinical study titled "A Study to Evaluate the Analgesic Efficacy and Safety of VM902A in Subjects With Osteoarthritis (OA) of the Knee". The purpose of this study is to evaluate the analgesic efficacy, safety, and tolerability of VM902A twice daily compared to placebo in subjects with moderate to severe chronic pain due to OA of the knee.
What is the current status of trial NCT02847702?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 75 participants. The study started on 2016-08. Estimated completion is 2016-11-22.
What interventions are being tested in trial NCT02847702?
The interventions under investigation include: Placebo (DRUG), VM902A 200-mg Capsules (DRUG), VM902A 400-mg Capsules (DRUG), Naproxen 500-mg Capsules (DRUG).
Who is sponsoring clinical trial NCT02847702?
This trial is sponsored by Purdue Pharma, which has 54 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.